



THE
BLADDER CANCER
COMPANY™

Photocure ASA: Market update

Oslo, Norway, 19 March 2020: The management of Photocure ASA (OSE:PHO) is following the Covid-19 situation closely and has implemented strict measures to ensure the safety of patients, customers, employees and business partners while maintaining an uninterrupted level of service and supply.

“The pandemic brings massive hardship to those affected by the virus, to families, communities and business. I would like to express our gratitude to all healthcare professionals fighting this disease around the globe. Our main priority is to ensure the uninterrupted supply of Hexvix®/Cysview®, in addition to maintaining our operations under a new framework. We are following the situation very closely and have implemented strict measure to ensure the safety of patients, customers, colleagues and partners. Scheduled bladder cancer treatments are vital to the patient care and most procedures are being performed as planned, with some postponements. However, we must expect this pandemic to affect the healthcare systems as the burden of managing the virus increases in the coming weeks and months,” says Daniel Schneider, President & Chief Executive Officer of Photocure.

Photocure’s production of Hexvix/Cysview is running at full capacity with no disruptions.

“There has been no disruption in our production schedules or shipments. Should we experience a temporary disruption, we have current inventory of Hexvix/Cysview that will last us to the end of 2020. Our key focus is to provide an uninterrupted service in treating patients with bladder cancer. In light of the seriousness of the current global health care crisis, the evolving circumstances will require a different way of working between our company and the health care providers we partner with. We intend to keep the lines of communications open and we plan to offer a variety of means to keep Blue Light Cystoscopy with Hexvix/Cysview in the forefront of patient care”, says Schneider.

Photocure has a strong cash position and carries no interest-bearing debt.

“Photocure has a strong underlying sales momentum in the U.S when returning to a normalized business environment, providing a solid platform for long-term growth. Short term business development and operations will be affected by this unprecedented crisis in various ways, but we remain confident in the significant commercial opportunities in the U.S. and reiterate our long-term ambitions”, Schneider concludes.

ENDS

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA

This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

For further information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Tel: + 1-609 759-6515

Email: ds@photocure.com

Erik Dahl

Chief Financial Officer

Tel: +47 450 55 000

Email: ed@photocure.no

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com